Hemorrhage irrigation reduces need for repeat operations in the most common neurosurgery emergency procedure
7.6.2024 07:43:22 EEST | HUS | Press release
According to a study published in The Lancet, irrigation during a craniostomy for a chronic subdural hemorrhage is worthwhile. The randomized comparative trial of five centers is historic in the field of neurosurgery in Finland.

The Finnish study of intraoperative irrigation versus drain alone after evacuation of chronic subdural haematoma (FINISH) investigated whether it is worthwhile to irrigate a chronic subdural hematoma during surgery
Half the patients had their hemorrhage irrigated and half did not. Otherwise, the procedure was carried out in the same way. The main result was that there was significantly less need for repeat procedures in patients who had their hemorrhage irrigated during surgery. Patients’ functional capacity and mortality did not differ between the groups.
The research project involved all Finnish neurosurgery units from the university hospitals of Helsinki, Kuopio, Tampere, Turku, and Oulu. A total of 589 patients with symptomatic chronic subdural hematoma were included in the study.
“Based on the results, we recommend that surgery be performed with irrigation as has been the current treatment protocol in Finland. The role of irrigation in surgery has not been previously studied in a randomized setting and the methods of intervention vary worldwide”, says Co-principal Investigator and Associate Professor Rahul Raj from HUS Neurocenter.
Chronic subdural hematoma requires neurosurgical treatment in the emergency department
Chronic subdural hematoma is the most common condition requiring neurosurgical treatment in the emergency department. Its symptoms may include difficulty walking, loss of strength, speech impediment, memory problems, headaches or epileptic seizures. Without treatment, a hematoma can be fatal. In a trephine craniostomy, a small hole is drilled in the skull and the clot is removed either by irrigating and then inserting a drain or by simply inserting a drain.
Co-principal investigator, Pihla Tommiska, MD, adds that trepanation is one of the most common neurosurgical procedures and the number of operations has increased dramatically in Finland in recent decades.
The study is historic in the field of neurosurgery, as a national randomized comparative study of five centers has never been conducted in Finland before.
The study was designed and implemented in collaboration with the Finnish Centre for Evidence-Based Orthopaedics (FICEBO) research group at the University of Helsinki and HUS. The group is internationally renowned for its randomized comparative studies
”When Rahul Raj, Pihla Tommiska and Kimmo Lönnrot presented their research idea in 2019, it was immediately clear to us that FICEBO would be putting its expertise and resources at the disposal of a great idea and ambitious young researchers. Our hope is that FINISH research can encourage young researchers to do more sustained research work," say Professor Teppo Järvinen and Research Director, Associate Professor Simo Taimela.
The study was published in The Lancet journal on June 6, 2024
Reference:
Raj R*, Tommiska P*, Koivisto T, Leinonen V, Danner N, Posti JP, Laukka D, Luoto TM, Rauhala M, Tetri S, Korhonen TK, Satopää J, Kivisaari R, Luostarinen T, Schwartz C, Czuba T, Taimela S, Lönnrot K*, Järvinen TLN* on behalf of the Finnish study of intraoperative irrigation versus drain alone after evacuation of CSDH (FINISH) study group. Burr-hole drainage with or without irrigation for chronic subdural haematoma (FINISH): a Finnish, nationwide, parallel-group, multicentre, randomised, controlled, non-inferiority trial. The Lancet 2024; 6 June
Link to the publication: https://doi.org/10.1016/S0140-6736(24)00686-X
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Keywords
Contacts
Rahul Raj, Associate Professor, Specialist in Neurosurgery
Email: rahul.raj@hus.fi
Pihla Tommiska, MD, Specializing Physician
Email: pihla.tommiska@helsinki.fi
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our more than 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Studie gav ny kunskap om immunförsvaret vid leukemi29.9.2026 08:26:54 EEST | Pressmeddelande
Forskare vid HUS Cancercentrum och Helsingfors universitet utredde hur immunsystemet hos patienter med akut myeloisk leukemi reagerade på experimentell immunterapi. Förändringar som hänför sig till terapiresponsen visade sig i andra immunceller än förväntat baserat på tidigare studier.
Tutkimus toi uutta tietoa leukemian immuunipuolustuksesta29.9.2026 08:26:54 EEST | Tiedote
HUSin Syöpäkeskuksen ja Helsingin yliopiston tutkijat selvittivät, miten akuuttia myelooista leukemiaa sairastavien potilaiden immuunijärjestelmä reagoi kokeelliseen immunoterapiaan. Hoitovasteeseen liittyvät muutokset näkyivät eri immuunisoluissa kuin aiempien tutkimusten perusteella olisi voitu odottaa.
Study provides new insights into the immune response in leukemia29.9.2026 08:26:54 EEST | Press release
Researchers at HUS Comprehensive Cancer Center and the University of Helsinki investigated how the immune systems of patients with acute myeloid leukemia (AML) respond to experimental immunotherapy. The study found that changes associated with treatment response were observed in different immune cell types than would have been expected based on previous research.
Genetiska undersökningar kan avslöja orsaken till plötslig oförklarlig död hos unga14.9.2026 09:18:15 EEST | Pressmeddelande
Den bakomliggande orsaken till plötslig oförklarlig död hos unga kan vara en sällsynt ärftlig sjukdom som nödvändigtvis inte kommer fram i vanliga undersökningar. Genetiska undersökningar är en viktig del särskilt i utredningen av plötsliga oväntade dödsfall hos unga. Genetiska undersökningar kan också bidra till att identifiera släktingar som omfattas av risken och förebygga eventuella allvarliga hjärthändelser.
Geenitutkimus voi paljastaa syyn nuoren selittämättömälle äkkikuolemalle14.9.2026 09:18:15 EEST | Tiedote
Nuoren selittämättömän äkkikuoleman taustalla voi olla harvinainen perinnöllinen sairaus, joka ei välttämättä tule esiin tavanomaisissa tutkimuksissa. Geenitutkimus on tärkeä osa erityisesti nuorten odottamattomien äkkikuolemien syyn selvittämisessä. Geenitutkimus voi myös auttaa tunnistamaan riskissä olevia sukulaisia ja ehkäistä mahdollisia vakavia sydäntapahtumia.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom